Bleeding Complications in Patients with Hematologic Malignancies

Abstract

Abnormalities of hemostasis are frequently encountered in patients with hematologic malignancies leading to both hemorrhagic and thrombotic adverse events. The prompt recognition and management of such complications, which have a negative impact on the morbidity and mortality of these patients, represents a major challenge for hematologists. This review describes the most important changes of hemostasis associated with hemorrhage in hematologic malignancies with particular emphasis on their contributory etiologic factors, complex pathogenic mechanisms, clinical manifestations, and therapeutic strategies. In particular, platelet and acquired coagulation abnormalities, bleeding complications in acute leukemia, and hematopoietic stem cell transplantation are discussed.

Keywords

bleeding - leukemia - hematologic malignancies - therapy

• References

• 1 Trousseau A. Phlegmasia alba dolens. In: Trousseau A, , ed. Clinique Medicinale de l'Hotel-Dieu de Paris. Paris, France: JB Bailliere et fils; 1865: 645-712
• 2 Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 2007; 24 (1) 29-38
• 3 Franchini M, Mannucci PM. Thrombin and cancer: from molecular basis to therapeutic implications. Semin Thromb Hemost 2012; 38 (1) 95-101
• 4 Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992; 18 (4) 353-372
• 5 Bick RL, Strauss JF, Frenkel EP. Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am 1996; 10 (4) 875-907
• 6 Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?. Thromb Res 2007; 120 (Suppl. 02) S99-S106
• 7 Green D. Management of bleeding complications of hematologic malignancies. Semin Thromb Hemost 2007; 33 (4) 427-434
• 8 Carlson KS, DeSancho MT. Hematological issues in critically ill patients with cancer. Crit Care Clin 2010; 26 (1) 107-132
• 9 Athale UH, Chan AKC. Hemorrhagic complications in pediatric hematologic malignancies. Semin Thromb Hemost 2007; 33 (4) 408-415
• 10 Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004; 18 (3) 153-167
• 11 Slichter SJ. Evidence based platelet transfusion guidelines. Hematology (Am Soc Hematol Educ Program) 2007; 172-178
• 12 Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997; 15 (3) 1143-1149
• 13 Rebulla P, Finazzi G, Marangoni F , et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337 (26) 1870-1875
• 14 Zumberg MS, del Rosario ML, Nejame CF , et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. Biol Blood Marrow Transplant 2002; 8 (10) 569-576
• 15 Diedrich B, Remberger M, Shanwell A, Svahn BM, Ringdén O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 × 10(9) per L versus 30 × 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005; 45 (7) 1064-1072
• 16 Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am 2007; 21 (4) 697-729 , vii
• 17 Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them?. Br J Haematol 2011; 154 (4) 425-440
• 18 British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122 (1) 10-23
• 19 Slichter SJ, Kaufman RM, Assmann SF , et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362 (7) 600-613
• 20 Estcourt LJ, Stanworth SJ, Murphy MF. Prophylactic platelet transfusions. Curr Opin Hematol 2010; 17 (5) 411-417
• 21 Bowen D, Culligan D, Jowitt S , et al; UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120 (2) 187-200
• 22 Pamphilon DH, Aparicio SR, Roberts BE, Menys VC, Tate G, Davies JA. The myelodysplastic syndromes—a study of haemostatic function and platelet ultrastructure. Scand J Haematol 1984; 33 (5) 486-491
• 23 Eby C, Blinder M. Hemostatic complications associated with paraproteinemias. Curr Hematol Rep 2003; 2 (5) 388-394
• 24 Glaspy JA. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am 1992; 6 (6) 1301-1314
• 25 DiMinno G, Coraggio F, Cerbone AM , et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986; 77 (1) 157-164
• 26 Adams T, Schutz L, Goldberg L. Platelet function abnormalities in the myeloproliferative disorders. Scand J Haematol 1974; 13 (3) 215-224
• 27 Wehmeier A, Scharf RE, Fricke S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. Haemostasis 1989; 19 (5) 251-259
• 28 Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev 2010; 24 (6) 227-232
• 29 Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 1978; 88 (1) 7-11
• 30 Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000; 110 (1) 116-124
• 31 Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82 (6) 1749-1757
• 32 Konkle BA. Acquired disorders of platelet function. Hematology (Am Soc Hematol Educ Program) 2011; 2011: 391-396
• 33 Cartoni C, Niscola P, Breccia M , et al. Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leuk Lymphoma 2009; 50 (3) 387-391
• 34 Slats AM, Egeler RM, van der Does-van den Berg A , et al. Causes of death—other than progressive leukemia—in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005; 19 (4) 537-544
• 35 Zakarija A, Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost 2007; 33 (4) 355-364
• 36 Franchini M, Veneri D, Lippi G. The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. Bone Marrow Transplant 2007; 39 (12) 729-735
• 37 de la Serna J, Montesinos P, Vellenga E , et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111 (7) 3395-3402
• 38 Tallman MS, Abutalib SA, Altman JK. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost 2007; 33 (4) 330-338
• 39 Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res 2010; 125 (Suppl. 02) S51-S54
• 40 Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16 (3) 463-482
• 41 Franchini M, Di Minno MND, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost 2010; 36 (4) 388-403
• 42 Tallman MS, Lefèbvre P, Baine RM , et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2 (8) 1341-1350
• 43 Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematology (Am Soc Hematol Educ Program) 2007; 151-157
• 44 Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005; 80 (1) 55-63
• 45 Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 2008; 395 (1-2) 14-18
• 46 Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112 (2) 250-255
• 47 Franchini M, Lippi G. Recent improvements in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35 (8) 806-813
• 48 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45 (3) 200-203
• 49 Bossi P, Cabane J, Ninet J , et al. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105 (5) 400-408
• 50 Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006; 81 (10) 768-773
• 51 Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 2001; 91 (6) 1067-1074
• 52 Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 2000; 124 (5) 730-734
• 53 Franchini M, Targher G, Manzato F, Lippi G. Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol 2008; 66 (3) 194-199
• 54 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012; 38 (5) 433-446
• 55 Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5 (5) 893-900
• 56 Franchini M, Sassi M, Dell'Anna P , et al. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. Semin Thromb Hemost 2009; 35 (1) 76-80
• 57 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121 (1) 21-35
• 58 Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63 (1) 47-52
• 59 Escobar MA. Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor?. Cancer 2012; 118 (2) 312-320
• 60 Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 2002; 28 (2) 227-238
• 61 Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007; 82 (5) 368-375
• 62 Federici AB, Rand JH, Bucciarelli P , et al; Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84 (2) 345-349
• 63 Federici AB, Rand JH, Mannucci PM. Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders. Hematol J 2001; 2 (6) 358-362
• 64 Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?. J Thromb Haemost 2008; 6 (4) 565-568
• 65 Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006; 43 (1) (Suppl. 01) S48-S58
• 66 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
• 67 Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92 (8) 2707-2711
• 68 Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32 (1) 45-59
• 69 Uprichard J, Perry DJ. Factor X deficiency. Blood Rev 2002; 16 (2) 97-110
• 70 Greipp PR, Kyle RA, Bowie EJ. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol 1981; 11 (4) 443-450
• 71 Comenzo RL. How I treat amyloidosis. Blood 2009; 114 (15) 3147-3157
• 72 Choufani EB, Sanchorawala V, Ernst T , et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97 (6) 1885-1887
• 73 Pihusch M. Bleeding complications after hematopoietic stem cell transplantation. Semin Hematol 2004; 41 (1) (Suppl. 01) 93-100
• 74 Bacigalupo A. Haemopoietic stem cell transplants: the impact of hemorrhagic complications. Blood Rev 2003; 17 (Suppl. 01) S6-S10
• 75 Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112 (3) 504-510
• 76 Pihusch R, Salat C, Schmidt E , et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74 (9) 1303-1309
• 77 Pihusch R, Salat C, Göhring P , et al. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut. Br J Haematol 2002; 117 (2) 469-476
• 78 Pihusch M, Bacigalupo A, Szer J , et al; F7BMT-1360 Trial Investigators. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3 (9) 1935-1944
• 79 Kwaan HC. Thrombosis in hematologic malignancies: risk and consequences. Int J Hematol Oncol 2012; 1: 1-9